References
- Raccah D. Efficacy and safety of lixisenatide in the treatment of Type 2 diabetes mellitus: a review of Phase III clinical data. Expert Rev Endocrinol Metab 2013;8(2):105-21
- Distiller LA, Ruus P; on behalf of the ACT6011 Study Group. Pharmacokinetics and pharmacodynamics of a new GLP-1 agonist AVE0010 in type 2 diabetes patients. Poster 520-P. Presented at the American Diabetes Association 68th Scientific Sessions; 2008. Available from: http://professional.diabetes.org/Content/Posters/2008/p520-P.pdf [Last accessed 12 August 2013]
- Thorkildsen C, Neve S, Larsen BD, et al. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J Pharmacol Exp Ther 2003;307(2):490-6
- Werner U, Haschke G, Herling AW, Kramer W. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of Type 2 diabetes. Regul Pept 2010;164(2–3):58-64
- Lorenz M, Pfeiffer C, Steinsträßer A, et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes – Relationship to postprandial glycemia. Regul Pept 2013;185(10):1-8
- Kapitza C, Coester HV, Poitiers F, et al. Pharmacodynamic characteristics of lixisenatide once daily vs liraglutide once daily in patients with T2DM inadequately controlled with metformin. Diabetes Obes Metab 2013;15(7):642-9
- Sanofi-Aventis Lyxumia EMA submission. Available fom www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002445/WC500140449.pdf [Last accessed 12 August 2013]
- American Diabetes Association. Standards of medical care in diabetes – 2013. Diabetes Care 2013;36(Suppl 1):S11-36
- Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35(6):1364-79